Abstract
Contrast media induced nephropathy is a common cause of kidney failure in hospitalized patients. It has been suggested that high-osmolality contrast media caused less nephropathies than low-osmolality ones. The cost-effectiveness of High- (Iodixanol) and Low-osmolality (Iohexol, Iopamidol and others) contrast media are compared by means of a decision tree. The analysis showed that Iopamidol and Iodixanol strategies dominated all the others. The incremental cost-effectiveness ratio of Iodixanol compared to Iopamidol is $31.637.306 per adicional avoided nephropathy. Iodixanol strategy is cost-effective for a budget per patient higher than $980.000, or 50 ml vial cost lower than $57.000, or willingness to pay per nephropathy avoided higher than $32.000.000.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
